Johnson & Johnson (JNJ)
Johnson & Johnson - FDA approves label expansion, cementingTREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
Johnson & Johnson - FDA approves label expansion, cementingTREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
📈 **POSITIVE** • Medium confidence analysis (68%) • Strong positive catalyst • High growth potential **Sentiment:** Positive (95%) **Content type:** General